{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:36:45Z","timestamp":1762353405974},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00520-023-08136-0","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T20:01:30Z","timestamp":1698350490000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study"],"prefix":"10.1007","volume":"31","author":[{"given":"Shiori","family":"Hishida-Sadaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serika","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"issue":"1","key":"8136_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"8136_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"8136_CR3","unstructured":"(2022) National comprehensive cancer network NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma, version 1. National Comprehensive Cancer Network, Plymouth Meeting, PA. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"issue":"8","key":"8136_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/bjc.1997.507","volume":"76","author":"M de Boer-Dennert","year":"1997","unstructured":"de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76(8):1055\u20131061. https:\/\/doi.org\/10.1038\/bjc.1997.507","journal-title":"Br J Cancer"},{"issue":"suppl 5","key":"8136_CR5","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC\/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119\u2013v133. https:\/\/doi.org\/10.1093\/annonc\/mdw270","journal-title":"Ann Oncol"},{"issue":"24","key":"8136_CR6","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38(24):2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"8136_CR7","unstructured":"NCCN clinical practice guidelines in oncology: antiemesis, version 1.2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf Accessed 23 Feb 2023"},{"issue":"1","key":"8136_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K, Imamura CK, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Iihara H, Ohtani S, Okuyama A, Ozawa K, Kim YI, Sasaki H, Shima Y, Takeda M, Nagasaki E, Nishidate T, Higashi T, Hirata K (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for antiemesis. Int J Clin Oncol 26(1):1\u201317. https:\/\/doi.org\/10.1007\/s10147-020-01818-3","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"8136_CR9","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1007\/s00520-013-1944-y","volume":"21","author":"N Silvestris","year":"2013","unstructured":"Silvestris N, Brunetti AE, Russano M, Nardulli P (2013) Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX. Support Care Cancer 21(11):2955\u20132956. https:\/\/doi.org\/10.1007\/s00520-013-1944-y","journal-title":"Support Care Cancer"},{"key":"8136_CR10","doi-asserted-by":"publisher","unstructured":"De Luca R, Volpe C, Mistretta O, Paci R, Ferrera G, Caputo V, Rosati G, Cicero G (2021) NEPA (netupitant\/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. Eur Rev Med Pharmacol Sci (16):5310\u20135317. https:\/\/doi.org\/10.26355\/eurrev_202108_26552","DOI":"10.26355\/eurrev_202108_26552"},{"issue":"67","key":"8136_CR11","doi-asserted-by":"publisher","first-page":"111346","DOI":"10.18632\/oncotarget.22795","volume":"8","author":"K Yoshida","year":"2017","unstructured":"Yoshida K, Iwashita T, Uemura S, Maruta A, Okuno M, Ando N, Iwata K, Kawaguchi J, Mukai T, Shimizu M (2017) A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget 8(67):111346\u2013111355. https:\/\/doi.org\/10.18632\/oncotarget.22795","journal-title":"Oncotarget"},{"key":"8136_CR12","unstructured":"US Department of Health and Human Services, National Institutes of Health \u2013 National Cancer Institute (2017) Common terminology criteria for adverse events (CTCAE) version 5.0. National Cancer Institute, Bethesda, MA, USA, 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"issue":"1","key":"8136_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-017-3857-7","volume":"26","author":"K Jordan","year":"2018","unstructured":"Jordan K, Bl\u00e4ttermann L, Hinke A, M\u00fcller-Tidow C, Jahn F (2018) Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis. Support Care Cancer 26(1):21\u201332. https:\/\/doi.org\/10.1007\/s00520-017-3857-7","journal-title":"Support Care Cancer"},{"issue":"6","key":"8136_CR14","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1634\/theoncologist.2018-0140","volume":"24","author":"T Yokoe","year":"2019","unstructured":"Yokoe T, Hayashida T, Nagayama A, Nakashoji A, Maeda H, Seki T, Takahashi M, Takano T, Abe T, Kitagawa Y (2019) Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Oncologist 24(6):e347\u2013e357. https:\/\/doi.org\/10.1634\/theoncologist.2018-0140","journal-title":"Oncologist"},{"issue":"5","key":"8136_CR15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M, CINV Study Group of Japan (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20(5):855\u2013865. https:\/\/doi.org\/10.1007\/s10147-015-0786-7","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"8136_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40487-022-00188-2","volume":"10","author":"A Hata","year":"2022","unstructured":"Hata A, Shiraishi Y, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T (2022) Exploratory analysis comparing Fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blind, Phase 3 study (CONSOLE). Oncol Ther 10(1):253\u2013262. https:\/\/doi.org\/10.1007\/s40487-022-00188-2","journal-title":"Oncol Ther"},{"issue":"1","key":"8136_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.6004\/jadpro.2014.5.1.8","volume":"5","author":"MV Brafford","year":"2014","unstructured":"Brafford MV, Glode A (2014) Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol 5(1):24\u201329. https:\/\/doi.org\/10.6004\/jadpro.2014.5.1.8","journal-title":"J Adv Pract Oncol"},{"issue":"5","key":"8136_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188\u2013195. https:\/\/doi.org\/10.1016\/j.suponc.2011.05.002","journal-title":"J Support Oncol"},{"key":"8136_CR19","doi-asserted-by":"publisher","first-page":"3439707","DOI":"10.1155\/2016\/3439707","volume":"2016","author":"G Babu","year":"2016","unstructured":"Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L, Jacob LA, Mallekavu SB, Dasappa L, Kiran PR, Sreevatsa A, Appachu S, Unnikrishnan V, Arroju V (2016) The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemother Res Pract 2016:3439707. https:\/\/doi.org\/10.1155\/2016\/3439707","journal-title":"Chemother Res Pract"},{"issue":"2","key":"8136_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"issue":"2","key":"8136_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(2):242\u2013249. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3","journal-title":"Lancet Oncol"},{"issue":"3","key":"8136_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ygyno.2020.01.004","volume":"156","author":"H Iihara","year":"2020","unstructured":"Iihara H, Shimokawa M, Hayasaki Y, Fujita Y, Abe M, Takenaka M, Yamamoto S, Arai T, Sakurai M, Mori M, Nakamura K, Kado N, Murase S, Shimaoka R, Suzuki A, Morishige KI (2020) Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: a multi-institution phase II study. Gynecol Oncol 156(3):629\u2013635. https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.004","journal-title":"Gynecol Oncol"},{"issue":"3","key":"8136_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","volume":"73","author":"RM Navari","year":"2013","unstructured":"Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73(3):249\u2013262. https:\/\/doi.org\/10.1007\/s40265-013-0019-1","journal-title":"Drugs"},{"issue":"2","key":"8136_CR24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/MPA.0b013e3182592c96","volume":"42","author":"G Aggarwal","year":"2013","unstructured":"Aggarwal G, Kamada P, Chari ST (2013) Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 42(2):198\u2013201. https:\/\/doi.org\/10.1097\/MPA.0b013e3182592c96","journal-title":"Pancreas"},{"key":"8136_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1600-0447.1997.tb05956.x","volume":"391","author":"D Nutt","year":"1997","unstructured":"Nutt D (1997) Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand Suppl 391:31\u201337. https:\/\/doi.org\/10.1111\/j.1600-0447.1997.tb05956.x","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"4","key":"8136_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2354.2006.00760.x","volume":"16","author":"RE Kast","year":"2007","unstructured":"Kast RE, Foley KF (2007) Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl) 16(4):351\u2013354. https:\/\/doi.org\/10.1111\/j.1365-2354.2006.00760.x","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"2","key":"8136_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10637-020-00903-8","volume":"38","author":"J Cao","year":"2020","unstructured":"Cao J, Ouyang Q, Wang S, Ragaz J, Wang X, Teng Y, Wang B, Wang Z, Zhang J, Wang L, Wu J, Shao Z, Hu X (2020) Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, m ulticenter phase III trial. Investig New Drugs 38(2):507\u2013514","journal-title":"Investig New Drugs"},{"issue":"3","key":"8136_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.22037\/ijpr.2020.113955.14584","volume":"19","author":"A Maleki","year":"2020","unstructured":"Maleki A, Ghadiyani M, Salamzadeh J, Salari S, Banihashem S, Tavakoli-Ardakani M (2020) Comparison of mirtazapine and olanzapine on nausea and vomiting following anthracycline-cyclophosphamide chemotherapy regimen in patients with breast Cancer. Iran J Pharm Res 19(3):451\u2013464. https:\/\/doi.org\/10.22037\/ijpr.2020.113955.14584","journal-title":"Iran J Pharm Res"},{"issue":"10","key":"8136_CR29","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1002\/onco.13851","volume":"26","author":"L Celio","year":"2021","unstructured":"Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, Collov\u00e0 E, Bertolini F, Petrelli F, Cassano A, Chiari R, Zanelli F, Pisconti S, Vittimberga I, Letizia A, Misino A, Gernone A, Bonizzoni E, Pilotto S, De Placido S, Bria E (2021) Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study. Oncologist 26(10):e1854\u2013e1861. https:\/\/doi.org\/10.1002\/onco.13851","journal-title":"Oncologist"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08136-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08136-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08136-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T10:10:14Z","timestamp":1702548614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08136-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["8136"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08136-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"4 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Iihara reported receiving personal fees from Taiho, Chugai, Yakult, Astellas, Eli Lilly, Daiichi Sankyo, AstraZeneca, Nippon Kayaku, Ono, and Nippon Boehringer Ingelheim and is receiving consulting fees to their institution from Taiho and Eisai outside the submitted work. Dr. Suzuki is receiving personal fees from Toa Eiyo, Asahi Kasei, Daiichi Sankyo, Pfizer, Eisai, Nippon Shinyaku, Celltrion Healthcare Japan, Otsuka, Sandoz, Tsumura, Nipro, Taiho, Kyowa-Kirin, Nippon Chemiphar, Japan Blood Products Organization, Takeda, and Nippon Boehringer Ingelheim and is receiving grants to their institution from Nippon Kayaku, Asahi Kasei, Chugai, Taiho, Daiichi Sankyo, Japan Blood Products Organization, Mochida, and Sun Pharma outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the guidelines for human studies adopted by the ethics committee of Gifu University Graduate School of Medicine and approved by the Japanese government (Institutional Review Board approval no. 2022\u2013286).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Given the retrospective nature of the study, obtaining the informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}}],"article-number":"657"}}